LEPU BIO-B (02157) saw its shares rise more than 6% during afternoon trading. At the time of writing, the stock was up 5.76%, trading at HK$4.41, with a turnover of HK$33.57 million. On February 26, the company announced that the clinical trial application for its self-developed innovative antibody-drug conjugate MRG006A, combined with immune checkpoint inhibitors and targeted therapies for patients with advanced liver cancer, has been officially approved by the National Medical Products Administration. This marks the first GPC3-targeted ADC drug to enter clinical stages globally and the first to be submitted for clinical trials in China. The approval signifies a shift from single-drug exploration to a new track of combination therapy, potentially offering a more effective new solution for patients with advanced liver cancer. Analysts noted that MRG006A is expected to advance precision treatment for liver cancer. The company's ADC pipeline is considered leading, with two ADC drugs already licensed overseas. Both MRG006A and MRG007 are novel ADCs developed based on the next-generation Hi-TOPi ADC platform, which is anticipated to enhance the company's value.